David A. Siegel Fate Therapeutics Inc Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,437,700 shares of FATE stock, worth $4.72 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,437,700
Previous 1,876,900
23.4%
Holding current value
$4.72 Million
Previous $7.02 Million
50.33%
% of portfolio
0.02%
Previous 0.02%
Shares
27 transactions
Others Institutions Holding FATE
# of Institutions
178Shares Held
124MCall Options Held
222KPut Options Held
48.6K-
Redmile Group, LLC San Francisco, CA13.2MShares$43.2 Million3.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.91MShares$32.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.1MShares$29.8 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA8.22MShares$26.9 Million3.14% of portfolio
-
State Street Corp Boston, MA8.04MShares$26.4 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $318M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...